Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
about
Neoadjuvant therapy in the treatment of breast cancerIntegration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results.Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancerEvaluating the response of neoadjuvant chemotherapy for treatment of breast cancer: are tumor biomarkers and dynamic contrast enhanced MR images useful predictive tools?Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.Positron Emission Tomography (PET) in OncologyPostmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.Pathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: The natural history of an elusive prognosticator.A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancerEfficiency of fluorodeoxyglucose positron emission tomography/computed tomography to predict prognosis in breast cancer patients received neoadjuvant chemotherapyHistologic Grade and Decrease in Tumor Dimensions Affect Axillary Lymph Node Status after Neoadjuvant Chemotherapy in Breast Cancer PatientsPhase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy.Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.Value of volume-based metabolic parameters for predicting survival in breast cancer patients treated with neoadjuvant chemotherapy.Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapyPrognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy.A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy.Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy.Feature selection for predicting tumor metastases in microarray experiments using paired design.Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients.DJ-1 protein expression as a predictor of pathological complete remission after neoadjuvant chemotherapy in breast cancer patients.Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting.Predictive factors of brain metastasis in patients with breast cancer.Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy.Improved Model for Predicting Axillary Response to Neoadjuvant Chemotherapy in Patients with Clinically Node-Positive Breast Cancer.Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy.Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0.
P2860
Q27694514-F4183D39-082D-42B4-839F-9CF5BE144640Q31092479-3F089C55-F014-493E-BE7E-D6217CC6C018Q33304691-6E8E4829-6125-4346-A0E3-A9B53F64EC62Q33814616-DAA390FA-34B8-40FB-9FD5-A8FE6215A39CQ34059719-9A9932A9-B7DC-4FB0-A7A6-80E8F95A7E0FQ34774840-F849CC50-0E4F-4348-BB5B-FB8221683FA3Q35087084-7FC6E1D1-0083-4177-B9D4-3D741C12CEC9Q35803615-23F58A00-AB0C-4664-9FDB-9D283CB3207FQ36204215-EF176FB6-36A9-4625-BBA5-8EA8EC5D61C0Q36403339-934A8C42-EE42-4827-BC0D-A21AB22701F6Q36441562-E0A40926-9CF9-4AAF-8900-C34228FE0669Q36972046-E0B58907-6CAB-4DA5-9722-1438C54325C6Q37241048-F93B40AC-0077-4B5D-863E-D70A98F9D585Q37276706-E3BD171B-B0BD-41F7-8AE7-23EEF8833A41Q37354718-7AB0986D-25D4-447E-9A94-8A125EDA13DAQ37467199-E46127B6-725A-4414-B6BE-E5C8C2FE71F0Q37547957-E3CDD27B-27FD-4B8F-BFCE-7D9958B191E3Q37662215-7C15F2A4-0F3C-4637-9FFA-2DB2B95484E0Q41483585-A539307C-5379-4C43-A834-E6181C1DEE13Q41982136-1B362AAA-A2C1-4454-972D-549452460177Q42510385-2CB5F9C1-8C74-4291-95AD-8E8C67B0E012Q43818230-7D46B6FD-793A-461C-BA81-D3784F2694D7Q44173035-3294C036-BB2B-46EF-A74C-214DA30D732DQ45771188-F3249FBD-9DB5-4F83-B0E4-3C9DD787B794Q45929654-A4E48897-1454-4F73-890B-4BF3EB21503FQ47139582-BDCBF8AA-546E-4A23-924F-DE9662621F43Q51808443-B12007C8-8FCD-4557-89E6-E8C8B14B350FQ55259793-9DCB30F5-9519-4A2B-9D06-E86879AFFEAF
P2860
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Factors predictive of distant ...... fter neoadjuvant chemotherapy.
@ast
Factors predictive of distant ...... fter neoadjuvant chemotherapy.
@en
type
label
Factors predictive of distant ...... fter neoadjuvant chemotherapy.
@ast
Factors predictive of distant ...... fter neoadjuvant chemotherapy.
@en
prefLabel
Factors predictive of distant ...... fter neoadjuvant chemotherapy.
@ast
Factors predictive of distant ...... fter neoadjuvant chemotherapy.
@en
P2093
P356
P1476
Factors predictive of distant ...... fter neoadjuvant chemotherapy.
@en
P2093
Alberto Ocana
Aman U Buzdar
Ana M Gonzalez-Angulo
Eugene H Huang
Gabriel N Hortobagyi
Henry M Kuerer
Massimo Cristofanilli
Paolo Morandi
Sean E McGuire
Shu-Wan Kau
P304
P356
10.1200/JCO.2005.11.124
P407
P577
2005-10-01T00:00:00Z